CN102558182B - 一种厄他培南钠晶型及其制备方法 - Google Patents
一种厄他培南钠晶型及其制备方法 Download PDFInfo
- Publication number
- CN102558182B CN102558182B CN201010620554.3A CN201010620554A CN102558182B CN 102558182 B CN102558182 B CN 102558182B CN 201010620554 A CN201010620554 A CN 201010620554A CN 102558182 B CN102558182 B CN 102558182B
- Authority
- CN
- China
- Prior art keywords
- ertapenem
- preparation
- crystal form
- methyl alcohol
- propyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (12)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010620554.3A CN102558182B (zh) | 2010-12-31 | 2010-12-31 | 一种厄他培南钠晶型及其制备方法 |
EP11854210.9A EP2660242B1 (en) | 2010-12-31 | 2011-12-22 | Crystalline form of ertapenem sodium and preparation method therefor |
RU2013135276/04A RU2583052C2 (ru) | 2010-12-31 | 2011-12-22 | Кристаллическая форма эртапенема натрия и способ ее получения |
ES11854210T ES2746045T3 (es) | 2010-12-31 | 2011-12-22 | Forma cristalina de ertapenem de sodio y método de preparación para la misma |
US13/997,957 US9012628B2 (en) | 2010-12-31 | 2011-12-22 | Crystalline form of ertapenem sodium and preparation method therefor |
PCT/CN2011/084430 WO2012089058A1 (zh) | 2010-12-31 | 2011-12-22 | 一种厄他培南钠晶型及其制备方法 |
JP2013546576A JP2014501265A (ja) | 2010-12-31 | 2011-12-22 | エルタペネムナトリウムの結晶形およびその調製方法 |
KR1020137017821A KR101929960B1 (ko) | 2010-12-31 | 2011-12-22 | 에르타페넴 나트륨의 결정형 및 이의 제조 방법 |
JP2016154850A JP6321735B2 (ja) | 2010-12-31 | 2016-08-05 | エルタペネムナトリウムの結晶形およびその調製方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010620554.3A CN102558182B (zh) | 2010-12-31 | 2010-12-31 | 一种厄他培南钠晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102558182A CN102558182A (zh) | 2012-07-11 |
CN102558182B true CN102558182B (zh) | 2015-02-11 |
Family
ID=46382301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010620554.3A Active CN102558182B (zh) | 2010-12-31 | 2010-12-31 | 一种厄他培南钠晶型及其制备方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9012628B2 (zh) |
EP (1) | EP2660242B1 (zh) |
JP (2) | JP2014501265A (zh) |
KR (1) | KR101929960B1 (zh) |
CN (1) | CN102558182B (zh) |
ES (1) | ES2746045T3 (zh) |
RU (1) | RU2583052C2 (zh) |
WO (1) | WO2012089058A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102363617B (zh) * | 2011-11-09 | 2013-09-18 | 上海希迈医药科技有限公司 | 一种厄他培南单钠盐结晶体及其制备方法 |
WO2014082226A1 (zh) * | 2012-11-28 | 2014-06-05 | 上海创诺医药集团有限公司 | 厄他培南单钠盐的纯化方法 |
CN103159770A (zh) * | 2013-03-22 | 2013-06-19 | 成都自豪药业有限公司 | 一种厄他培南单钠盐晶型 |
IN2013MU03862A (zh) | 2013-12-11 | 2015-07-31 | Unimark Remedies Ltd | |
WO2015105720A1 (en) * | 2014-01-07 | 2015-07-16 | Hospira Inc. | Stabilised carbapenem compositions |
KR101587420B1 (ko) * | 2014-08-20 | 2016-01-22 | 주식회사 대웅제약 | 에르타페넴-함유 동결건조제제의 제조방법 |
KR20170014842A (ko) * | 2015-07-31 | 2017-02-08 | 주식회사 대웅제약 | 개선된 에르타페넴 주사제의 제조방법 |
CN113416193B (zh) * | 2021-08-23 | 2021-12-17 | 凯莱英医药集团(天津)股份有限公司 | 厄他培南钠新晶型及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1752090A (zh) * | 2005-10-20 | 2006-03-29 | 上海交通大学 | 尔他培南钠盐的制备方法 |
WO2008062279A2 (en) * | 2006-11-20 | 2008-05-29 | Orchid Chemicals & Pharmaceuticals Limited | An improved process for the preparation of carbapenem antibiotic |
WO2009150630A2 (en) * | 2008-06-11 | 2009-12-17 | Ranbaxy Laboratories Limited | Process for preparing a carbapenem antibiotic composition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9202298D0 (en) * | 1992-02-04 | 1992-03-18 | Ici Plc | Antibiotic compounds |
WO1999045010A1 (en) * | 1998-03-02 | 1999-09-10 | Merck & Co., Inc. | Process for synthesizing carbapenem antibiotics |
US6504027B1 (en) | 1998-03-02 | 2003-01-07 | Merck & Co., Inc. | Decarboxylation process for synthesizing carbapenem antibiotics |
AR035728A1 (es) | 2001-01-16 | 2004-07-07 | Merck & Co Inc | Proceso perfeccionado para la sintesis de carbapenem |
CN100387599C (zh) * | 2001-09-26 | 2008-05-14 | 麦克公司 | 用于生产碳青霉烯化合物的方法 |
JP2005508321A (ja) * | 2001-09-26 | 2005-03-31 | メルク エンド カムパニー インコーポレーテッド | 結晶形態のエルタペネムナトリウム |
EP2209787A4 (en) * | 2007-10-08 | 2011-08-03 | Orchid Chemicals & Pharm Ltd | METHOD FOR PRODUCING A CARBAPENEM ANTIBIOTICS |
-
2010
- 2010-12-31 CN CN201010620554.3A patent/CN102558182B/zh active Active
-
2011
- 2011-12-22 US US13/997,957 patent/US9012628B2/en active Active
- 2011-12-22 WO PCT/CN2011/084430 patent/WO2012089058A1/zh active Application Filing
- 2011-12-22 EP EP11854210.9A patent/EP2660242B1/en active Active
- 2011-12-22 JP JP2013546576A patent/JP2014501265A/ja active Pending
- 2011-12-22 ES ES11854210T patent/ES2746045T3/es active Active
- 2011-12-22 RU RU2013135276/04A patent/RU2583052C2/ru active
- 2011-12-22 KR KR1020137017821A patent/KR101929960B1/ko active IP Right Grant
-
2016
- 2016-08-05 JP JP2016154850A patent/JP6321735B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1752090A (zh) * | 2005-10-20 | 2006-03-29 | 上海交通大学 | 尔他培南钠盐的制备方法 |
WO2008062279A2 (en) * | 2006-11-20 | 2008-05-29 | Orchid Chemicals & Pharmaceuticals Limited | An improved process for the preparation of carbapenem antibiotic |
WO2009150630A2 (en) * | 2008-06-11 | 2009-12-17 | Ranbaxy Laboratories Limited | Process for preparing a carbapenem antibiotic composition |
Also Published As
Publication number | Publication date |
---|---|
US9012628B2 (en) | 2015-04-21 |
KR101929960B1 (ko) | 2018-12-17 |
RU2583052C2 (ru) | 2016-05-10 |
EP2660242A4 (en) | 2014-07-02 |
JP6321735B2 (ja) | 2018-05-09 |
CN102558182A (zh) | 2012-07-11 |
JP2017025068A (ja) | 2017-02-02 |
WO2012089058A1 (zh) | 2012-07-05 |
RU2013135276A (ru) | 2015-02-10 |
EP2660242A1 (en) | 2013-11-06 |
ES2746045T3 (es) | 2020-03-04 |
KR20140029367A (ko) | 2014-03-10 |
US20130281427A1 (en) | 2013-10-24 |
EP2660242B1 (en) | 2019-06-26 |
JP2014501265A (ja) | 2014-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102558182B (zh) | 一种厄他培南钠晶型及其制备方法 | |
CN102363617B (zh) | 一种厄他培南单钠盐结晶体及其制备方法 | |
CN102659818B (zh) | 一种盐酸头孢替安晶体化合物及其制备方法及含该化合物的药物组合物 | |
CN104530086B (zh) | 头孢孟多酯钠化合物的新晶型及其结晶制备方法 | |
CN103435632B (zh) | 一种头孢呋辛酯的制备方法 | |
CN102268018A (zh) | 头孢克肟的结晶方法 | |
CN101585845B (zh) | 美洛西林的制备方法 | |
CN103012437A (zh) | 抗菌药物头孢西丁酸的制备方法 | |
CN103172530B (zh) | 一种托芬那酸的制备方法 | |
CN102336757A (zh) | 一种稳定晶型的美罗培南化合物 | |
CN102617327B (zh) | 右旋布洛芬化合物及其制法 | |
CN102702203A (zh) | 一种美罗培南的精制方法 | |
CN114195720A (zh) | 一种依托咪酯的纯化方法 | |
CN102010345A (zh) | 一种动态动力学拆分制备d-苯丙氨酸的方法 | |
CN102363621B (zh) | 头孢米诺钠六水合物及其制备方法和含有该水合物的药物组合物 | |
WO2014094659A1 (zh) | 一种美罗培南三水合物晶体的制备方法 | |
CN114751818B (zh) | 一种壬二酸alpha晶型的制备方法 | |
CN103554218B (zh) | N(2)-l-丙氨酰-l-谷氨酰胺晶型及其制备方法 | |
CN104788454A (zh) | 一种厄他培南单钠盐新晶型及其制备工艺 | |
CN104045547B (zh) | 一种丙酮酸钠重结晶制取方法 | |
CN103664947A (zh) | 一种碳青霉烯抗菌药物的新晶型及其制备方法 | |
CN104788453B (zh) | 厄他培南单钠盐一锅法制备工艺 | |
CN106432266B (zh) | 一种阿洛西林钠晶体及其制备方法 | |
CN106336363A (zh) | 一种沙芬酰胺甲磺酸盐晶型c及其制备方法 | |
CN105585524A (zh) | 一种由孟鲁司特酸制备孟鲁司特钠的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ZHONGNUO PHARMACEUTICAL (SHIJIAZHUANG) CO., LTD., Effective date: 20140616 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140616 Address after: 050051 No. 276 West Zhongshan Road, Hebei, Shijiazhuang Applicant after: Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. of CSPC Group Applicant after: Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Shiyao Group Address before: 050051 No. 276 West Zhongshan Road, Hebei, Shijiazhuang Applicant before: Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. of CSPC Group |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |